Evaxion reports 89% T-cell response at three years
Key points
- Evaxion reported sustained immune responses at three-year follow-up in its Phase 2 EVX-01 advanced melanoma trial, with 89% of vaccine targets generating specific T-cell responses.
- All six patients in the one-year extension maintained their clinical responses without tumor progression, following earlier results showing a 75% objective response rate among 16 patients.
- Evaxion plans to present its three-year findings at the ESMO 2026 Congress on October 24, followed by a clinical data webinar on October 29.
Evaxion (NASDAQ:EVAX) reported sustained three-year responses in its Phase 2 EVX-01 melanoma trial, with 89% of vaccine targets generating specific T-cell responses.
The 89% finding compared with 86% at two years, while earlier trial results showed a 75% objective response rate.
Six of 12 initial responders entered a one-year extension receiving EVX-01 alone, with all six maintaining clinical responses without tumor progression.
Evaxion plans to present the three-year findings on October 24, 2026, while continuing to evaluate potential development partnerships.
Earlier results showed complete responses in 25% of 16 enrolled patients, with tumor reduction observed in 15 participants.
Evaxion previously reported that 92% of responders maintained clinical benefit at two years and scheduled additional immune data presentations for November 2026.
